ArticlePloS one2014
Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Viral associations in multiple sclerosis: pathogenetic mechanisms and therapeutic implications.Virology journal · 2026Review
- Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis.Scientific reports · 2026Article
- HHV-6 and EBV reactivation in relapsing remitting multiple sclerosis: Disability, progression, and inflammation links.iScience · 2025Article
- From Viral Infection to Autoimmune Reaction: Exploring the Link between Human Herpesvirus 6 and Autoimmune Diseases.Microorganisms · 2024Review
- Review
- Immune response profiling of HERV-W envelope proteins in multiple sclerosis: potential biomarkers for disease progression.Frontiers in immunology · 2024Article
- A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.Frontiers in immunology · 2024Article
- The Probable Infectious Origin of Multiple Sclerosis.NeuroSci · 2023Review
- Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort:Frontiers in immunology · 2023Article
- Genetic influences on disease course and severity, 30 years after a clinically isolated syndrome.Brain communications · 2023Article
- Seizures and multiple sclerosis‑more than an epidemiological association (Review).Experimental and therapeutic medicine · 2022Review
- Role of Microglia in Herpesvirus-Related Neuroinflammation and Neurodegeneration.Pathogens (Basel, Switzerland) · 2022Review
- Human herpesvirus 6 infection as a trigger of multiple sclerosis: an update of recent literature.BMC neurology · 2022Review
- Human Herpesvirus 6A Is a Risk Factor for Multiple Sclerosis.Frontiers in immunology · 2022Review
- Evolution of antibody titres against Epstein-Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients.Scientific reports · 2021Article
- Article
- Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis.Frontiers in immunology · 2021Article
- Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.Clinical microbiology reviews · 2020Review
- The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy.Scandinavian journal of immunology · 2020Review
- The Presence of Human Herpesvirus 6 in the Brain in Health and Disease.Biomolecules · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the titers of the IgG and IgM antibodies against human herpesvirus 6A/B (HHV-6A/B) in multiple sclerosis (MS) patients treated with different disease modified therapies (DMTs) along two-years of follow-up.
methodsWe collected 2163 serum samples from 596 MS; for 301 MS patients a 2-years follow-up was performed. Serum samples of 337 healthy controls were also analyzed. Anti-HHV-6A/B IgG and IgM were analyzed by ELISA (Panbio).
resultsWe found that 129/187 (69.0%) MS patients with a decrease of the anti-HHV-6A/B IgG titers after 2-years with DMTs were free of relapses and progression vs. 46/113 (40.7%) of MS patients with an increase of the anti-HHV-6A/B IgG titers (p = 0.0000015); the higher significance was found for natalizumab. Furthermore, we found that anti-HHV-6A/B IgG titers reached their highest value two weeks before the relapse (p = 0.0142), while the anti-HHV-6A/B IgM titers reached their highest value one month before the relapse (p = 0.0344).
conclusionThe measurement of the anti-HHV-6A/B IgG titers could be a good biomarker of clinical response to the different DMTs. The increase of the anti-HHV-6A/B IgG and IgM titers predicts the upcoming clinical relapses. However, further longitudinal studies are needed to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.